ABVC BioPharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ABVC Nasdaq 2830 www.abvcpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ABVC BioPharma, Inc.

ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 - Nov 3rd, 2025 6:00 am
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950 - Oct 31st, 2025 5:00 am
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology - Oct 17th, 2025 5:30 am
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production - Oct 8th, 2025 5:30 am
ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression Therapies - Sep 23rd, 2025 5:11 pm
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model - Sep 19th, 2025 5:30 am
ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025 - Aug 29th, 2025 5:30 am
BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration - Aug 27th, 2025 12:25 am
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal - Aug 22nd, 2025 5:30 am
ABVC BioPharma First Half 2025 Earnings: US$0.19 loss per share (vs US$0.36 loss in 1H 2024) - Aug 15th, 2025 6:10 am
ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025 - Aug 14th, 2025 5:30 am
BioKey Stands as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff Shifts - Aug 8th, 2025 5:00 am
ABVC BioPharma Gains Confidence From International Investors to Support Growth Path - Aug 6th, 2025 5:30 am
OncoX Deepens ABVC Alliance - Aug 1st, 2025 5:00 am
ABVC BioPharma Strengthens Oncology Partnership With $100,000 Milestone Payment From OncoX BioPharma - Jul 24th, 2025 7:00 am
ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program - Jul 18th, 2025 7:00 am
ABVC BioPharma Receives $150K Milestone From AiBtl, Bringing Total Licensing Revenue to $846K Across Strategic Partnerships - Jul 10th, 2025 3:32 pm
ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology - Jun 26th, 2025 6:00 am
ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment - Jun 24th, 2025 6:00 am
ABVC BioPharma Expands Oncology Portfolio as Affiliate OncoX Acquires Patented Lycopenoid Platform Valued at $4.06 Million - Jun 6th, 2025 6:30 am